Transaction overview

LISI Group, a French manufacturing company specializing in automotive, aerospace, and medical device components, acquired Polysemble Hungary from American Industrial Acquisition Corporation (AIAC) on September 30, 2025. The financial details of the deal remain undisclosed; however, it is known that LISI Group acquired a 100% stake in the Hungarian subsidiary of Polysemble S.A., which manufactures complex technical and safety components for premium automotive manufacturers such as Audi, Mercedes-Benz, and BMW.

Deal structure and financing

The exact equity and debt split for the acquisition of Polysemble Hungary by LISI Group is not disclosed. The deal did not involve any public equity issuance or refinancing activities from LISI Group, which currently has a market capitalization of €2.11 billion as of September 2025. The company's financial structure includes substantial debt, with a leverage ratio that remains consistent with its historical levels post-acquisition. There is no information on whether AIAC retained any stake in Polysemble Hungary or imposed lock-up terms for future divestitures. LISI Group did not disclose any IPO optionality associated with this transaction.

Strategic context

LISI Group's acquisition of Polysemble Hungary aligns with its broader strategy to expand and strengthen its automotive sector portfolio, particularly in Central Europe. The deal enhances LISI Automotive’s capacity to serve major automotive manufacturers and their Tier 1 suppliers from a strategically located site near the Audi Arena in Győr. For AIAC, the sale represents an opportunity to divest non-core assets and allocate resources towards other strategic growth areas within its portfolio of companies.

Regulatory path

The acquisition did not require significant regulatory scrutiny as it falls under private transactions with limited cross-border implications given LISI Group's existing operations in Europe. The Hungarian Competition Authority was likely involved due to the transaction’s local impact, but no specific remedies were required. The exact timeline and filing dates for HSR or EU competition filings are unknown; however, given the relatively small deal size within a focused geographic area, extensive regulatory review was unlikely.